Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025

Xilio Therapeutics, Inc.

Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.
Preliminary Phase 1 data for XTX301 (IL-12) in 34 patients: no DLTs, no Grade 4/5 AEs, sustained IFN-gamma signaling.
No measurable activated XTX301 in peripheral circulation; majority of AEs Grade 1/2 (flu-like, CRS, transaminitis).
Cash runway guidance updated: existing cash + equivalents expected to fund operations into Q3 2025.
Initial Phase 2 data for vilastobart (XTX101) + atezolizumab in MSS CRC to be presented at ASCO GI (Jan 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.